Vanguard Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$60.9M Buy
2,011,253
+236,380
+13% +$7.24M ﹤0.01% 1795
2026
Q2
$61.7M Buy
1,774,873
+245,980
+16% +$7.26M ﹤0.01% 1821
2026
Q1
$35.3M Buy
+1,528,893
New +$34.5M ﹤0.01% 2045

Other funds holding AVBP

Vanguard Capital Management's AVBP Position: Q3 2026 in Review

Vanguard Capital Management increased its ArriVent BioPharma (AVBP) stake by 13% in Q3 2026, buying an estimated $7.24M and bringing the position to 2,011,253 shares worth $60.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Vanguard Capital Management first reported a position in AVBP in Q1 2026 and has held it in 3 quarters since. The position peaked at $61.7M in Q2 2026. 153 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Vanguard Capital Management held 2,011,253 shares of ArriVent BioPharma worth $60.9M as of Q3 2026.
  • Vanguard Capital Management bought 236,380 ArriVent BioPharma shares in Q3 2026, an estimated $7.24M.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1795 holding.
  • Vanguard Capital Management first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's ArriVent BioPharma position peaked at $61.7M in Q2 2026.
  • 153 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.